428 related articles for article (PubMed ID: 26079530)
1. Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect.
Wang Y; Zhang H; Hao J; Li B; Li M; Xiuwen W
Drug Deliv; 2016 May; 23(4):1398-403. PubMed ID: 26079530
[TBL] [Abstract][Full Text] [Related]
2. Prodrug-based nano-drug delivery system for co-encapsulate paclitaxel and carboplatin for lung cancer treatment.
Zhang W; Li C; Shen C; Liu Y; Zhao X; Liu Y; Zou D; Gao Z; Yue C
Drug Deliv; 2016 Sep; 23(7):2575-2580. PubMed ID: 26056720
[TBL] [Abstract][Full Text] [Related]
3. Which one performs better for targeted lung cancer combination therapy: pre- or post-bombesin-decorated nanostructured lipid carriers?
Du J; Li L
Drug Deliv; 2016 Jun; 23(5):1799-809. PubMed ID: 26455787
[TBL] [Abstract][Full Text] [Related]
4. Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA.
Shao Z; Shao J; Tan B; Guan S; Liu Z; Zhao Z; He F; Zhao J
Int J Nanomedicine; 2015; 10():1223-33. PubMed ID: 25709444
[TBL] [Abstract][Full Text] [Related]
5. Combined using of paclitaxel and salinomycin active targeting nanostructured lipid carriers against non-small cell lung cancer and cancer stem cells.
Zhou J; Sun M; Jin S; Fan L; Zhu W; Sui X; Cao L; Yang C; Han C
Drug Deliv; 2019 Dec; 26(1):281-289. PubMed ID: 30880491
[TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of doxorubicin into tumor cells by nanostructured lipid carriers conjugated to anti-EGFRvIII monoclonal antibody.
Abdolahpour S; Toliyat T; Omidfar K; Modjtahedi H; Wong AJ; Rasaee MJ; Kashanian S; Paknejad M
Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):89-94. PubMed ID: 28296511
[TBL] [Abstract][Full Text] [Related]
7. Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer.
Yang XY; Li YX; Li M; Zhang L; Feng LX; Zhang N
Cancer Lett; 2013 Jul; 334(2):338-45. PubMed ID: 22776563
[TBL] [Abstract][Full Text] [Related]
8. Nanocarrier-Based Combination Chemotherapy for Resistant Tumor: Development, Characterization, and Ex Vivo Cytotoxicity Assessment.
Raikwar S; Vyas S; Sharma R; Mody N; Dubey S; Vyas SP
AAPS PharmSciTech; 2018 Nov; 19(8):3839-3849. PubMed ID: 30280350
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of baicalein and doxorubicin by hyaluronic acid decorated nanostructured lipid carriers for breast cancer therapy.
Liu Q; Li J; Pu G; Zhang F; Liu H; Zhang Y
Drug Deliv; 2016 May; 23(4):1364-8. PubMed ID: 25874959
[TBL] [Abstract][Full Text] [Related]
10. Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells.
Zhang XG; Miao J; Dai YQ; Du YZ; Yuan H; Hu FQ
Int J Pharm; 2008 Sep; 361(1-2):239-44. PubMed ID: 18586075
[TBL] [Abstract][Full Text] [Related]
11. Sclareol is a potent enhancer of doxorubicin: Evaluation of the free combination and co-loaded nanostructured lipid carriers against breast cancer.
Borges GSM; Silva JO; Fernandes RS; de Souza ÂM; Cassali GD; Yoshida MI; Leite EA; de Barros ALB; Ferreira LAM
Life Sci; 2019 Sep; 232():116678. PubMed ID: 31344429
[TBL] [Abstract][Full Text] [Related]
12. Lung cancer combination therapy: doxorubicin and β-elemene co-loaded, pH-sensitive nanostructured lipid carriers.
Cao C; Wang Q; Liu Y
Drug Des Devel Ther; 2019; 13():1087-1098. PubMed ID: 31118562
[No Abstract] [Full Text] [Related]
13. Synergistic combination therapy of lung cancer: Cetuximab functionalized nanostructured lipid carriers for the co-delivery of paclitaxel and 5-Demethylnobiletin.
Guo S; Zhang Y; Wu Z; Zhang L; He D; Li X; Wang Z
Biomed Pharmacother; 2019 Oct; 118():109225. PubMed ID: 31325705
[TBL] [Abstract][Full Text] [Related]
14. Nanostructured lipid carrier co-delivering paclitaxel and doxorubicin restrains the proliferation and promotes apoptosis of glioma stem cells via regulating PI3K/Akt/mTOR signaling.
Chang L; Zhang Y; Li M; Zhao X; Wang D; Liu J; Zhou F; Zhang J
Nanotechnology; 2021 Mar; 32(22):. PubMed ID: 33690190
[TBL] [Abstract][Full Text] [Related]
15. Nanostructured lipid carriers as novel drug delivery system for lung cancer gene therapy.
Han Y; Li Y; Zhang P; Sun J; Li X; Sun X; Kong F
Pharm Dev Technol; 2016; 21(3):277-81. PubMed ID: 25560648
[TBL] [Abstract][Full Text] [Related]
16. Pluronic-based functional polymeric mixed micelles for co-delivery of doxorubicin and paclitaxel to multidrug resistant tumor.
Chen Y; Zhang W; Huang Y; Gao F; Sha X; Fang X
Int J Pharm; 2015 Jul; 488(1-2):44-58. PubMed ID: 25899286
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of doxorubicin, docosahexaenoic acid, and α-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicity.
Lages EB; Fernandes RS; Silva JO; de Souza ÂM; Cassali GD; de Barros ALB; Miranda Ferreira LA
Biomed Pharmacother; 2020 Dec; 132():110876. PubMed ID: 33113428
[TBL] [Abstract][Full Text] [Related]
18. Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment.
Feng T; Tian H; Xu C; Lin L; Xie Z; Lam MH; Liang H; Chen X
Eur J Pharm Biopharm; 2014 Nov; 88(3):1086-93. PubMed ID: 25305583
[TBL] [Abstract][Full Text] [Related]
19. Tumor-targeted polymeric nanostructured lipid carriers with precise ratiometric control over dual-drug loading for combination therapy in non-small-cell lung cancer.
Liang Y; Tian B; Zhang J; Li K; Wang L; Han J; Wu Z
Int J Nanomedicine; 2017; 12():1699-1715. PubMed ID: 28280336
[TBL] [Abstract][Full Text] [Related]
20. A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation.
Li Q; Lv S; Tang Z; Liu M; Zhang D; Yang Y; Chen X
Int J Pharm; 2014 Aug; 471(1-2):412-20. PubMed ID: 24905776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]